185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial
| Autor: | Rugo, H.S., Jacot, W., Tokunaga, E., Sohn, J., Cardoso, F., Xu, B., Losada, M.J. Vidal, Gil, M.J., Ueno, N.T., Prat, A., Moore, H., Hasler-Strub, U., Cameron, D.A.A., Lindman, H., Mezei, K., Rajagopalan, R., Orbegoso, C.M.A., Cheng, F-C., Puri, A., Modi, S. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|